Comparison of Pamidronate With Zoledronic Acid for Transplant Related Bone Loss Prevention

Bayside Health56 enrolled

Overview

The purpose of this trial is to see whether zoledronic acid is better than pamidronate to treat low bone density in heart and lung transplant patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Osteopenia Complications of Heart-lung Transplant Other Complications of Lung Transplant

Interventions

zoledronic acid vs pamidronateDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * reduced bone density as indicated by a bone density T score \<-1.in either the lumbar spine or femoral neck * have undergone or are on the waiting list for heart or lung transplantation * are receiving adequate calcium and vitamin D therapy * have provided written informed consent prior to participation in the trial Exclusion Criteria: * untreated hypogonadism, hypothyroidism or hyperthyroidism * acute or major organ rejection or intercurrent illness * pregnancy or breastfeeding

Outcomes

Primary Outcomes

Bone mineral density of lumbar spine at 12 months as measured by DEXA.

Secondary Outcomes

Bone mineral density of femoral neck at 12 months as measured by DEXA.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.